<DOC>
	<DOC>NCT00171288</DOC>
	<brief_summary>The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population</brief_summary>
	<brief_title>Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Patients aged 1875 Primary hypercholesterolemia Signed informed consent Patients involved in clinical trials 3 months prior to inclusion Patients treated with drugs specified in protocol Fertile women not using contraceptive methods Other protocol defined in and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Dyslipidemia, ezetimibe, inflammatory markers, fluvastatin</keyword>
</DOC>